Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposis sarcoma, and multiple myeloma. Co-founded by one of Doxils co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.